{
    "clinical_study": {
        "@rank": "31748", 
        "brief_summary": {
            "textblock": "Background:\n\n      Pilot study to assess feasibility for combining treatment modalities that should be\n      synergistic (radiation and thermal ablation).\n\n      Thermal ablation with Radiofrequency Ablation (RFA) and microwave ablation (MWA) are\n      standard treatments for focal neoplasms in the liver.\n\n      High volume or scattered locations of tumor burden results in inability to successfully use\n      this technology for a large proportion of patients with hepatic neoplasms.\n\n      Methods to enhance treatment volumes could be advantageous in potentially increasing the\n      indications for thermal ablation or the number of patients benefitting from local ablation.\n\n      Primary objective:\n\n      To determine the safety of combining 2 standard therapies (thermal ablation and external\n      beam radiation therapy) for liver neoplasms up to 10 cm diameter.\n\n      Eligibility:\n\n      Patients greater than 18 years of age with pathologically proven unresectable primary or\n      metastatic hepatic neoplasms\n\n      Patients whose extent of hepatic metastases represents approximately less than 60% of total\n      liver volume AND whose extrahepatic metastatic disease is determined to be minimal\n\n      ECOG performance status of less than or equal to 2 and a life expectancy of more than 3\n      months\n\n      Patients with a history of chemotherapy, radiation therapy, or biological therapy for at\n      least 4 weeks prior to starting study treatments, and 4 weeks after treatments Patients must\n      not have an acute, critical illness\n\n      If clinical or imaging evidence for cirrhosis present, then Bilirubin must be less than 3\n      mg/dl and Child-Pugh Classification A, (Class B &  C are excluded)\n\n      Design:\n\n      Patients will undergo external beam radiation as well as thermal ablation according to\n      standard operating procedures of the NCI and NIH CC.\n\n      Patients will be monitored using the standard imaging studies when clinically warranted.\n\n      Patients may be treated with a second (or more) thermal ablation procedure ALONE if it is\n      deemed beneficial for the patient by the investigator.\n\n      The sample size will be 10 evaluable patients"
        }, 
        "brief_title": "Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Liver Neoplasms", 
            "Hepatic Cancer", 
            "Liver Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Background:\n\n      Pilot study to assess feasibility for combining treatment modalities that should be\n      synergistic (radiation and thermal ablation).\n\n      Thermal ablation with Radiofrequency Ablation (RFA) and microwave ablation (MWA) are\n      standard treatments for focal neoplasms in the liver.\n\n      High volume or scattered locations of tumor burden results in inability to successfully use\n      this technology for a large proportion of patients with hepatic neoplasms.\n\n      Methods to enhance treatment volumes could be advantageous in potentially increasing the\n      indications for thermal ablation or the number of patients benefitting from local ablation.\n\n      Primary objective:\n\n      To determine the safety of combining 2 standard therapies (thermal ablation and external\n      beam radiation therapy) for liver neoplasms up to 10 cm diameter.\n\n      Eligibility:\n\n      Patients greater than 18 years of age with pathologically proven unresectable primary or\n      metastatic hepatic neoplasms\n\n      Patients whose extent of hepatic neoplasms represents approximately less than 60% of total\n      liver volume AND whose extrahepatic metastatic disease is determined to be minimal\n\n      ECOG performance status of less than or equal to 2 and a life expectancy of more than 3\n      months\n\n      Patients with a history of chemotherapy, radiation therapy to liver, or biological therapy\n      must have had last dose/ treatment for at least 14 days prior to starting study treatments.\n\n      Patients must not have an acute, critical illness\n\n      If clinical or imaging evidence for cirrhosis present, then Bilirubin must be less than 3\n      mg/dl and Child-Pugh Classification A, (Class B &  C are excluded)\n\n      Design:\n\n      Patients will undergo external beam radiation as well as thermal ablation according to\n      standard operating procedures of the NCI and NIH CC.\n\n      Patients will be monitored using the standard imaging studies when clinically warranted.\n\n      Patients may be treated with a second (or more) thermal ablation procedure ALONE if it is\n      deemed beneficial for the patient by the investigator.\n\n      The sample size will be 10 evaluable patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA:\n\n        Patients with hepatic-dominant neoplasms where the life limiting component of the disease\n        is hepatic neoplasms\n\n        Patients must have unresectable hepatic lesions or must be deemed unable or unadvisable to\n        undergo surgical resection\n\n        Have 5 or fewer lesions and with no single lesion greater than 10 cm in maximum diameter\n\n        Patients with extrahepatic neoplasms or an unresected primary lesion will be considered\n        eligible if the extrahepatic disease is minimal and stable\n\n        Serum Creatinine less than 2.0 mg/dl unless the measured creatinine clearance is greater\n        than 60 ml/min.\n\n        Absolute neutrophil count (ANC) greater than or equal to1500/m3 without help of\n        Filgastrim, hemoglobin greater than 8 g/dL, and platelet count greater than or equal to\n        75,000 m3\n\n        Bilirubin less than 3 mg/dl, and AST and ALT less than 5 X upper limit of normal except in\n        the presence of obstructive liver neoplasms where ALT/AST may be up to 10 X the upper\n        limit of normal.\n\n        Prothrombin Time (PT) within 2 seconds of the upper limit normal (INR less than 1.8)\n\n        Extent of hepatic neoplasms is approximately less than 60% of total hepatic volume\n\n        Patients must have pathology proof of neoplasm.  If proof of pathology is unavailable,\n        histopathological confirmation of liver  neoplasm may not be requisite in the setting of\n        clinical or radiological characteristics that are highly suggestive of a neoplastic\n        diagnosis, with such designation determined by PI and a medical or surgical  oncologist,\n        with the NCI multidisciplinary gastrointestinal tumor board review, in the event of\n        absence of such consensus.\n\n        Patients referred for ablation or radiation of liver neoplasm\n\n        ECOG performance status less than or equal to 2\n\n        Life expectancy greater than 3 months\n\n        At least 18 years of age\n\n        Age less than 85 years\n\n        Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their\n        malignancy for at least 28 days prior to treatment and must have recovered from all\n        clinically significant side effects of therapeutic and diagnostic interventions.\n\n        EXCLUSION CRITERIA:\n\n        Portal Vein Occlusion or other contraindications to thermal ablation or radiation Prior\n        selective internal radiation therapy (SIRT) with Yttrium-90 or prior radiation to the\n        liver\n\n        Prior biliary diversion surgery\n\n        Patients requiring ongoing chronic anticoagulation will not be eligible.\n\n        Standard clinical screening procedures will be performed, and when it is clinically\n        low-risk to do so, patients will be taken off of aspirin or NSAIDS for a week prior to\n        RFA, as per clinical standard.\n\n        Patients with active bacterial infections with systemic manifestations (malaise, fever,\n        leucocytosis) are not eligible until completion of appropriate therapy.\n\n        Any exclusion criteria for radiation or for ablation, such as ataxia telengiectasia,\n        active connective tissue disease, or inflammatory bowel disease, or other known conditions\n        which predispose to radiation toxicities\n\n        Patients with an acute, critical illness\n\n        Pregnant or nursing mothers will not be eligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862718", 
            "org_study_id": "130079", 
            "secondary_id": "13-CC-0079"
        }, 
        "intervention": [
            {
                "description": "N/A", 
                "intervention_name": "Thermal Ablation", 
                "intervention_type": "Procedure"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "Standard External Beam Radiation Therapy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fusion", 
            "Tracking", 
            "Ablation", 
            "Hepatic Metastases"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2013-CC-0079.html"
        }, 
        "location": {
            "contact": {
                "email": "prpl@mail.cc.nih.gov", 
                "last_name": "For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)", 
                "phone": "800-411-1222", 
                "phone_ext": "TTY8664111010"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms", 
        "overall_contact": {
            "email": "garciacr@mail.nih.gov", 
            "last_name": "Charisse Garcia, R.N.", 
            "phone": "(301) 594-4511"
        }, 
        "overall_contact_backup": {
            "email": "bwood@mail.cc.nih.gov", 
            "last_name": "Bradford Wood, M.D.", 
            "phone": "(301) 496-7739"
        }, 
        "overall_official": {
            "affiliation": "National Institutes of Health Clinical Center (CC)", 
            "last_name": "Bradford Wood, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the safety of combining 2 standard therapies (thermal ablation and external    beam radiation therapy) for liver neoplasms up to 10 cm diameter", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "reference": [
            {
                "PMID": "12599233", 
                "citation": "Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, Kohara K, Shigenobu S, Ishibashi K, Arima T. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003 Mar 1;97(5):1253-62."
            }, 
            {
                "PMID": "9426432", 
                "citation": "Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5."
            }, 
            {
                "PMID": "7698628", 
                "citation": "Buscarini L, Rossi S, Fornari F, Di Stasi M, Buscarini E. Laparoscopic ablation of liver adenoma by radiofrequency electrocauthery. Gastrointest Endosc. 1995 Jan;41(1):68-70. No abstract available."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862718"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institutes of Health Clinical Center (CC)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}